Y-mAbs Therapeutics (YMAB) Misses Q2 EPS by 27c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.94), $0.27 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $10.8 million versus the consensus estimate of $11.23 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook